Aktive Positionen von Oliver Schlüter
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Finanzdirektor/CFO | 10.09.2015 | - |
Karriereverlauf von Oliver Schlüter
Ehemalige bekannte Positionen von Oliver Schlüter
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Finanzdirektor/CFO | 25.11.2009 | 01.05.2010 |
| DZ Bank AG (Securities) | Analyst-Equity | 31.01.2006 | 31.01.2006 |
Statistik
International
| Deutschland | 4 |
Operativ
| Director of Finance/CFO | 2 |
| Analyst-Equity | 1 |
Sektoral
| Health Technology | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
| DZ Bank AG (Securities) | Finance |
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Health Technology |
- Börse
- Insiders
- Oliver Schlüter
- Erfahrung